Previous article
Berdazimer (Zelsuvmi) for the Treatment of Molluscum Contagiosum
Mar 2025
Next article
Caring for Adults With Intellectual Disabilities in the Community
FPIN's Clinical Inquiries
From the Family Practice Inquiries Network

Zuranolone (Zurzuvae) for Treatment of Severe Postpartum Depression in Adults

Serena Fang, MD
Roya Sharifian, MD
Vivian Cheng, PharmD
Jon O. Neher, MD

American Family Physician. 2025;111(3):265-266.

Author disclosure: No relevant financial relationships.

SERENA FANG, MD; ROYA SHARIFIAN, MD; VIVIAN CHENG, PHARMD; and JON O. NEHER, MD Valley Family Medicine, Renton, Washington

Address correspondence to Vivian Cheng, PharmD, at vivian_cheng@valleymed.org.

Author disclosure: No relevant financial relationships.

  1. 1.Zou J, Yang L, Yang G, et al. The efficacy and safety of some new GABAkines for treatment of depression: a systematic review and meta-analysis from randomized controlled trials. Psychiatry Res. 2023;328:115450.
  2. 2.Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021;78(9):951-959.
  3. 3.Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180(9):668-675.
  4. 4.American College of Obstetricians and Gynecologists. Practice advisory: zuranolone for the treatment of postpartum depression. August 2023. Updated January 30, 2024. Accessed January 6, 2025. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/08/zuranolone-for-the-treatment-of-postpartum-depression
  5. 5.US Food and Drug Administration. Highlights of prescribing information. Zurzuvae (zuranolone) capsules, for oral use. July 2024. Accessed January 9, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217369s001lbl.pdf

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (https://www.cebm.net).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to https://www.fpin.org or email questions@fpin.org.

Copyright © Family Physicians Inquiries Network. Used with permission.

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Clinical Inquiries published in AFP is available at https://www.aafp.org/afp/fpin.

Previous article
Berdazimer (Zelsuvmi) for the Treatment of Molluscum Contagiosum
Mar 2025
Next article
Caring for Adults With Intellectual Disabilities in the Community

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.